Trial · NCT05681481
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent AEs, SAEs and AESIs | Efgartigimod PH20 SC | AE | 40 | Participants | |
| Number of Participants With Treatment-emergent AEs, SAEs and AESIs | Efgartigimod PH20 SC | SAE | 13 | Participants | |
| Number of Participants With Treatment-emergent AEs, SAEs and AESIs | Efgartigimod PH20 SC | AESI | 25 | Participants | |
| Number of Participants Who Discontinued Treatment Because of Safety Concerns | Efgartigimod PH20 SC | 4 | Participants | ||
| Number of Participants Achieving CRoff for ≥ 8 Weeks | Efgartigimod PH20 SC | 3 | Participants | ||
| Number of Participants Achieving CRoff or PRoff for ≥ 8 Weeks | Efgartigimod PH20 SC | 3 | Participants | ||
| Number of Participants Achieving CRmin for ≥ 8 Weeks | Efgartigimod PH20 SC | 4 | Participants | ||
| Number of Participants Achieving Complete Remission While Off Both Oral Corticosteroids and Efgartigimod PH20 SC for ≥ 8 Weeks | Efgartigimod PH20 SC | 10 | Participants | ||
| Number of Participants Achieving CR or PR While Off Both OCS and Efgartigimod PH20 SC for ≥ 8 Weeks | Efgartigimod PH20 SC | 10 | Participants | ||
| Duration of Sustained Remission | Efgartigimod PH20 SC | NA | 95% Confidence Interval 54.0 to ? | days | |
| Number of Participants Who Relapsed | Efgartigimod PH20 SC | 37 | Participants | ||
| Time to Relapse | Efgartigimod PH20 SC | 169.0 | 95% Confidence Interval 108.0 to 301.0 | days | |
| BPDAI Activity Score, Percent Change From Baseline to Last Assessment | Efgartigimod PH20 SC | 0.15 | Standard Deviation 118.361 | Percent change | |
| IGA-BP Score at Last Assessment | Efgartigimod PH20 SC | 0 - Clear | 28 | Participants | |
| IGA-BP Score at Last Assessment | Efgartigimod PH20 SC | 1 - Almost clear | 8 | Participants | |
| IGA-BP Score at Last Assessment | Efgartigimod PH20 SC | 2 - Mild | 19 | Participants | |
| IGA-BP Score at Last Assessment | Efgartigimod PH20 SC | 3 - Moderate | 4 | Participants | |
| IGA-BP Score at Last Assessment | Efgartigimod PH20 SC | 4 - Severe | 4 | Participants | |
| Itch NRS 24-hour Average Score, Change From Baseline to Last Assessment | Efgartigimod PH20 SC | 0.3 | Standard Deviation 3.07 | score on a scale | |
| Number of Participants Who Failed Treatment | Efgartigimod PH20 SC | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05681481/results